Clapham House
ADDInterim results from Clapham House, the firm led by proven restaurateur David Page, show profits up 339% to £1.2m on sales up 140% to £20.6m.
Page is only part way through his five-year plan for domination of the UK restaurant market and the rate of expansion is accelerating: ‘You open five in the first year, 12 the next, then 20 in the third year and 30 in the fourth, so by the fifth year you’re able to open 50 new sites a year,’ he explains. That’s an exciting future for investors to look forward to.
In the six months to October, CPH increased its estate to 66, and expects to advance this to 72 by the year-end. The company then intends to open 20-25 the following financial year, all funded by internal cashflow. All four brands (Gourmet Burger Kitchen, Bombay Bicycle Club, Tootsies and Real Greek) are 'popular' and make cash ‘straight away’, Page confirms – apart from the Bicycle Club delivery kitchens, which ‘take three years but eventually provide the highest return on capital’ – so cashflow for the half-year was £1.7m compared to £0.6m for the whole of the previous financial year.
Of the Tootsies estate obtained as part of the £25m acquisition of Urban Dining at the start of the period, all will benefit from a new menu and seven have been refurbished, one converted to a GBK and one sold.
Independent broker Investec forecasts that the full year will produce £47.1m turnover, feeding through to £3.1m of pre-tax profit and 6.2p of earnings per share. This rises to £6.2m profits and 12.2p earnings for 2008. CPH’s forward rating of 43 times earnings for the full year therefore falls to a more palatable 22 the year after, but the rate of growth here is so impressive that the significance of these ratios is limited.
A Christmas pick in Growth Company Investor last year at 165p, the shares have been strong performers and are still worth picking up.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £90.69m
PE Forecast: 43.2
Share price: 268p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
